Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Alzamend Neuro ( (ALZN) ).
On April 17, 2026, Alzamend Neuro held its annual meeting of stockholders, where investors elected seven directors to serve until the next annual meeting and ratified Haskell & White LLP as the independent auditor for the fiscal year ending April 30, 2026. Stockholders also approved on an advisory basis executive compensation, the 2025 Stock Incentive Plan, equity issuances to directors and executive officers for Nasdaq compliance, a potential reverse stock split at a ratio of one-for-two to one-for-ten to be implemented by April 16, 2027 at the board’s discretion, and the option to adjourn the meeting to solicit additional votes if needed, signaling broad shareholder support for the company’s capital structure flexibility and governance measures.
These approvals strengthen Alzamend Neuro’s ability to manage its share structure, maintain exchange listing standards, and incentivize management and directors, which may be important as the company advances its drug development programs. The authorization of a reverse stock split in particular underscores the company’s focus on capital markets positioning and could affect existing shareholders through potential changes in share price and liquidity dynamics.
The most recent analyst rating on (ALZN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Alzamend Neuro stock, see the ALZN Stock Forecast page.
More about Alzamend Neuro
Alzamend Neuro, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer’s disease and related neurological disorders. The company operates in the life sciences sector, concentrating on innovative therapeutic candidates aimed at addressing unmet medical needs in central nervous system conditions.
Average Trading Volume: 150,232
Technical Sentiment Signal: Sell
Current Market Cap: $3.88M
For a thorough assessment of ALZN stock, go to TipRanks’ Stock Analysis page.